MedPath

Pradaxa

These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively. See full prescribing information for PRADAXA Capsules. PRADAXA (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010

Approved
Approval ID

ba74e3cd-b06f-4145-b284-5fd6b84ff3c9

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 28, 2023

Manufacturers
FDA

Boehringer Ingelheim Pharmaceuticals Inc.

DUNS: 603175944

Products 3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dabigatran etexilate mesylate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0597-0355
Application NumberNDA022512
Product Classification
M
Marketing Category
C73594
G
Generic Name
dabigatran etexilate mesylate
Product Specifications
Route of AdministrationORAL
Effective DateNovember 28, 2023
FDA Product Classification

INGREDIENTS (1)

DABIGATRAN ETEXILATE MESYLATEActive
Quantity: 75 mg in 1 1
Code: SC7NUW5IIT
Classification: ACTIR

dabigatran etexilate mesylate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0597-0108
Application NumberNDA022512
Product Classification
M
Marketing Category
C73594
G
Generic Name
dabigatran etexilate mesylate
Product Specifications
Route of AdministrationORAL
Effective DateNovember 28, 2023
FDA Product Classification

INGREDIENTS (1)

DABIGATRAN ETEXILATE MESYLATEActive
Quantity: 110 mg in 1 1
Code: SC7NUW5IIT
Classification: ACTIR

dabigatran etexilate mesylate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0597-0360
Application NumberNDA022512
Product Classification
M
Marketing Category
C73594
G
Generic Name
dabigatran etexilate mesylate
Product Specifications
Route of AdministrationORAL
Effective DateNovember 28, 2023
FDA Product Classification

INGREDIENTS (1)

DABIGATRAN ETEXILATE MESYLATEActive
Quantity: 150 mg in 1 1
Code: SC7NUW5IIT
Classification: ACTIR

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Pradaxa - FDA Drug Approval Details